Monthly Newsletter

Well-constructed newsletter packed with breakthrough events from biopharma companies along decision making people contacts.

REQUEST DEMO

Monthly Newsletter

The Doloxe’s Advanced Therapies newsletter covers financing, licensing deals, merger & acquisitions, drug development, regulatory updates, key people hiring and new companies. Excellent resource for investors and people interested in clinical development news.

Key developments and newer technologies encourage scientific fraternity, leadership team and services engage more among themselves
Understand latest trends by geography, drug phase, molecule nature and disease area
Act as business leads within industry help to achieve within timelines

Benefits for Healthcare Players:

Start-up and Contract Research & Manufacturing Companies:
Monthly newsletter with drug developments and contacts keep them up-to-date with material events and business leads.
Market size projections help you to get the business scope for raising investment.
Search for planned trials with CROs as collaborator within your sales territory.
Biopharma Companies:
Informed with competitor events and execute corporate planning by keeping a track on future drug and clinical trials milestones expected from your competitors.
Customize your key events tracking based on companies in the same technology or disease or target.
Generic Drugs and API manufacturer:
Helps you to plan drug portfolio management or strategy based on key pipeline class of drugs (future market share) and disease market by country.
Support you with planned trials by disease, sponsors/collaborators.
API, & Intermediates Manufactures:
Key pipeline class of drugs (future market share); disease market by key countries.
Generics by active ingredient in US, EU, & Japan, and Patent expiry for key pipeline and marketed drugs.
Financial Firms:
Keep track on early stage biotech companies and proactively evaluate companies based on future events and clinical trial success rates.
Set alerts for material events at companies within your portfolio or competing companies that may affect the valuation of your portfolio companies.